NAP1L2 and inflammatory bowel disease: The results showed that in the IBD mice managed with metformin‐treated OE‐Nap1l2 BMSCs, weight loss was ameliorated, DAI was decreased, and shortening of the colon length was also alleviated (Figure 6A–D).